061IC - Management of Common Prostate Cancer Dilemmas

Learning Objectives:

• Utilize prostate specific antigen (PSA) and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.
• Classify the principles of “risk-adapted” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores and specific genetic mutations (e.g., BRCA1/2).
• Explain the roles of magnetic resonance imaging (MRI), high frequency ultrasound and transperineal approaches to improve prostate biopsy.
• Explain the use of positron emission tomography (PET) imaging to better stage men with high-risk disease, to better characterize men with biochemical recurrence and to guide metastasis-directed therapy in men with oligometastatic disease.
• Describe how to choose and sequence secondary and tertiary hormonal, chemotherapeutic, immunological and/or targeted therapies (e.g., PARP inhibitors) in men with metastatic and castrate resistant prostate cancer.